Open Access

[Retracted] Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway

  • Authors:
    • Liyan Du
    • Xiaomei Li
    • Linhong Zhen
    • Weiling Chen
    • Lingguang Mu
    • Yang Zhang
    • Ailin Song
  • View Affiliations

  • Published online on: March 31, 2025     https://doi.org/10.3892/mmr.2025.13508
  • Article Number: 143
  • Copyright : © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Related Articles

Journal Cover

June-2025
Volume 31 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Du L, Li X, Zhen L, Chen W, Mu L, Zhang Y and Song A: [Retracted] Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. Mol Med Rep 31: 143, 2025.
APA
Du, L., Li, X., Zhen, L., Chen, W., Mu, L., Zhang, Y., & Song, A. (2025). [Retracted] Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. Molecular Medicine Reports, 31, 143. https://doi.org/10.3892/mmr.2025.13508
MLA
Du, L., Li, X., Zhen, L., Chen, W., Mu, L., Zhang, Y., Song, A."[Retracted] Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway". Molecular Medicine Reports 31.6 (2025): 143.
Chicago
Du, L., Li, X., Zhen, L., Chen, W., Mu, L., Zhang, Y., Song, A."[Retracted] Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway". Molecular Medicine Reports 31, no. 6 (2025): 143. https://doi.org/10.3892/mmr.2025.13508